报告人：Prof. Min Wu

报告题目：To save the body by eating themselves for protecting infection

报告时间：2017年11月19日上午8:30

报告地点：省药用植物生物技术重点实验室103会议室

主办单位：江苏省药食植物生物技术国家重点实验室培育点、生命科学学院、科技处

报告人简介：

Prof. Min Wu, PhD

School of Medicine and Health Sciences, University of North Dakota.

Associate editor: Nanomedicine NBM (Elsevier, Since 2011)

Associate editor J Immunology (Since 2015)

Academic editor, PLOS ONE (Since 2012)

Editorial board member: American Journal of Respiratory Molecular Cell Biology

Editorial board member: Current Stem Cell Research and Therapy

Frontier Immunology Review Editor (since 2011)

Frontier Pharmacology Review Editor (since 2013)

The Wu lab investigates fundamental mechanisms of P. aeruginosa (PA) respiratory infection involving autophagy, epigenetics and ubiquitination, especially during phagocytosis, inflammatory response, and bacterial clearance. The lab studies macrophage function (phagosome maturation) relating to signaling molecules including TLRs, Lyn, annexin A2, caveolin 1, and lipid rafts. The lab also investigates how epigenetic modifications (miRNAs) are associated with pathogenesis of lung infection or other diseases (asthma, chronic obstructive pulmonary disease, and cancer). Considering bacterial virulence and pathogenesis, the lab asks how CRISPR-Cas adaptive immune systems regulate pathogen endogenous gene expression to dictate bacterial invasion and alter the host defense using a combination approach (cell biology, advanced microscopy, negative genetics, and RNA-seq). They have published serious of papers in top journals, like P.N.A.S., Nature Communications, Nature Microbiology, Cell Host Microbe, Cancer Research, Nucleic Acid Res, Cell Research, PLoS Pathogens, PLoS Biology, et al. 

The long-term goal is to develop novel therapeutic strategies (e.g., antimicrobial compounds, peptides, and gene delivery) and vaccines (e.g., attenuated bacterial strains) that target to our newly identified signal pathways using new nanoparticles in diagnostics, imaging, and therapy.